Abstract
Introduction. The use of next-generation sequencing technologies (NGS) to study parasite populations and their response and evolution to interventions is important to support malaria control and elimination efforts. While whole genome sequencing (WGS) is optimal in terms of assessing the entire genome, it is costly for numerous samples. Targeted approaches selectively enriching for sequence of interest are more affordable but sometimes lack adequate information content for key analyses. Methods. We have developed a highly-multiplexed molecular inversion probe (MIP) panel (IBC2FULL) targeting single nucleotide polymorphisms (SNPs) with ≥ 5% minor allele frequency (MAF) in sub-Saharan African regions from publicly available Plasmodium falciparum WGS. We optimized the panel alone and in combination with antimalarial drug resistance MIPs in laboratory P. falciparum strains at different parasitemias, and validated it by sequencing field isolates from Democratic Republic of Congo, Ethiopia, Ghana, Mali, Rwanda, Tanzania and Uganda and evaluating population structure, identity-by-descent (IBD), signals of selection, and complexity of infection (COI) Results. The new panel IBC2FULL consisted of 2,128 MIP microhaplotypes (containing 4,264 common SNPs) spaced by 5.1 - 18.4 kb across the entire genome. While these microhaplotypes were developed based on variation from sub-Saharan African WGS, 59.3% (2,529) of SNPs were also common in South-East Asia. The MIPs were balanced to produce more uniform and higher depth coverage at low parasitemia (100 parasites/μL) along with MIPs targeting antimalarial drug resistance genes. Comparing targeted regions extracted from public WGS, IBC2FULL provided higher resolution of local population structure in sub-Saharan Africa than current PCR-based targeted sequencing panels. Sequencing field samples, IBC2FULL approximated WGS measures of relatedness, population structure, and COI. Interestingly, genome-wide analysis of extended haplotype homozygosity detected the same major peaks of selection as WGS. We also chose a subset of 305 high performing probes to create a core panel (IBC2CORE) that produced high-quality data for basic population genomic analysis and accurate estimation of COI. Discussion. IBC2FULL and IBC2CORE provide an improved platform for malaria genomic epidemiology and biology that can approximate WGS for many applications and is deployable for malaria molecular surveillance in resource-limited settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by Brown Institutional Research Funding and NIH R01AI137410, R01AI139520 and R01AI139179.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For Mali samples, study was approved by the ethics committee of the Faculty of Medicine and Odontostomatology and the Faculty of Pharmacy of Bamako (INV--037659). For Tanzania samples, ethical approval was obtained from the Medical Research Coordinating Committee (MRCC) of the Tanzanian National Institute for Medical Research (NIMR; NIMR/HQ/R.8c/Vol.I/976). For Ghana samples, ethical approval was obtained from the Noguchi Memorial Institute for Medical Research (NMIMR) Institutional Review Board (IRB) (GHSERC:014/03/22NMIMR-IRB CPN 030/21-22). For DRC and Rwanda samples, ethical approval was obtained from the Rwanda National Ethics Committee (reference 1497/RNEC/2024), the Medical Coordinating Committee of the National Institute for Medical Research Tanzania, the MUST Research Ethics Committee, Ethics Committee of Ecole de Santé Publique de Kinshasa and the Institutional Review Board at Brown University (RI, USA; IRB 2107003059). We also used sequencing data deposited in public repositories by published studies.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos